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cium channels is up-regulated in dorsal root ganglion neu-
rons following peripheral somatosensory nerve damage, in
several animal models of neuropathic pain. The a2d-1 pro-
tein has a mainly presynaptic localization, where it is asso-
ciated with the calcium channels involved in
neurotransmitter release. Relevant to the present study,
a2d-1 has been shown to be the therapeutic target of the
gabapentinoid drugs in their alleviation of neuropathic pain.
These drugs are also used in the treatment of certain epilep-
sies. In this study we therefore examined whether the level
or distribution of a2d-1 was altered in the hippocampus fol-
lowing experimental induction of epileptic seizures in rats,
using both the kainic acid model of human temporal lobe
epilepsy, in which status epilepticus is induced, and the tet-
anus toxin model in which status epilepticus is not involved.
The main ﬁnding of this study is that we did not identify
somatic overexpression of a2d-1 in hippocampal neurons
in either of the epilepsy models, unlike the upregulation of
a2d-1 that occurs following peripheral nerve damage to both
somatosensory and motor neurons. However, we did
observe local reorganization of a2d-1 immunostaining in
the hippocampus only in the kainic acid model, where it
was associated with areas of neuronal cell loss, as indicated
by absence of NeuN immunostaining, dendritic loss, as
identiﬁed by areas where microtubule-associated protein-2
immunostaining was missing, and reactive gliosis, deter-
mined by regions of strong OX42 staining.http://dx.doi.org/10.1016/j.neuroscience.2014.03.013
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INTRODUCTION
Voltage-gated calcium (CaV) channels consist of three
subgroups, the CaV1, 2 and 3 classes (Catterall, 2011).
Most of these channels, apart from CaV1.1 which is a
skeletal muscle channel, are involved in neuronal
function, with their most prevalent functions being in
excitation–transcription coupling (CaV1.2), synaptic
transmission (CaV2 channels), and regulation of neuronal
excitability and pacemaker activity (CaV3 channels).
Because of their key roles in neuronal function, it is not
surprising that a number of diﬀerent calcium channels
have been implicated in the pathogenesis of various
forms of epilepsy, in both humans and in animal models.
These channels include T-type (CaV3) channels (Su
et al., 2002; Tringham et al., 2012; Cheong and Shin,
2013), P/Q-type (CaV2.1) channels (Imbrici et al., 2004;
Rajakulendran et al., 2012), and the auxiliary subunits, b4
(Escayg et al., 1998) and a2d-2 (Barclay et al., 2001;
Edvardson et al., 2013). Furthermore several calcium
channels are either actual or potential targets for
therapeutic intervention (Cain and Snutch, 2012; Powell
et al., 2013).
The CaV auxiliary a2d and b subunits, both of which
have four isoforms, are associated with the ‘‘high
voltage activated’’ CaV1 (L-type) and CaV2 classes (N,
P/Q and R-type) of calcium channel, but are not thought
to be associated with CaV3 (T-type) calcium channels.
Both auxiliary subunits increase plasma membrane
expression of the CaV1 and CaV2 channels, and
inﬂuence their biophysical properties (Dolphin, 2012b).
Of relevance to the potential pathological roles of a2d
subunits, the a2d-1 isoform is up-regulated following
peripheral somatosensory nerve damage (for review see
Bauer et al., 2010), whereas mutations in a2d-2 have
been linked to absence epilepsy (Barclay et al., 2001;. All rights reserved.
rg/licenses/by/3.0/).
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have also been reported to fulﬁll other functions
independent of calcium channels (Eroglu et al., 2009;
Kurshan et al., 2009), and are likely to interact with
other binding partners, including thrombospondins
(Eroglu et al., 2009).
Both a2d-1 and a2d-2 represent binding sites for the
anti-epileptic a2d ligand drugs gabapentin and
pregabalin (Brown et al., 1998; Klugbauer et al., 2003).
These drugs are used as adjunct therapy in several
forms of epilepsy, particularly drug-resistant partial
seizures (Marson et al., 2000; Arroyo et al., 2004;
Taylor et al., 2007). They are also widely used in the
treatment of neuropathic pain resulting from peripheral
nerve damage of various origins, such as trauma,
trigeminal neuralgia, diabetes-induced nerve damage,
and chronic pain following viral infection, including post-
herpetic neuralgia (Moore et al., 2009, 2011). They
have also been used for alleviation of chronic pain
resulting both from human immunodeﬁciency virus
(HIV) infection and as a side eﬀect of some of the
anti-HIV drugs (Schutz and Robinson-Papp, 2013).
Chronic neuropathic pain resulting from cancer
chemotherapeutic drugs, including paclitaxel and
cisplatin, is also treated with gabapentinoid drugs
(Fallon, 2013).
The mechanism of action of the gabapentinoid drugs
in the treatment of epilepsies remains unclear. In this
study we wished to examine whether the level or
distribution of a2d-1 was altered following experimental
induction of epileptic seizures in rats, since a change in
a2d-1 level or distribution might contribute to the anti-
epileptic mechanism of action of gabapentinoid drugs, in
a similar way to their therapeutic action in neuropathic
pain (see Discussion). It was not possible to examine
changes in distribution of a2d-2 protein in parallel in this
study, as no antibodies suitable for
immunohistochemistry are currently available.
We chose to use the rat kainic acid model of human
temporal lobe epilepsy, in which spontaneous seizures
have been found to occur following a latent period after
the initial induction by kainic acid of persistent seizures,
known as status epilepticus (Buckmaster and Dudek,
1997). In this model, rats ﬁrst develop status epilepticus,
and then consistently develop spontaneous seizures
which exhibit a gradual increase in spontaneous
frequency in the subsequent weeks (Dudek and Staley,
2012). This model is relevant because gabapentin is
known to be eﬀective against seizures induced by this
means (Cilio et al., 2001). For comparison, we also
used the tetanus toxin model of temporal lobe epilepsy
(Jeﬀerys et al., 1995), in which status epilepticus is not
induced (Finnerty and Jeﬀerys, 2002).EXPERIMENTAL PROCEDURES
Kainic acid treatment
Ten adult male Sprague–Dawley rats weighing
approximately 250 g were injected with kainic acid
(2.5 mg/kg i.p.) to induce status epilepticus. Injections
were repeated once per hour until 5–9 Racine stage III/IV/V seizures per hour have occurred (Luttjohann et al.,
2009). After 40–60 min from the onset of status
epilepticus (near-continuous motor epileptic activity),
diazepam (10 mg/kg, i.p.) was injected repeatedly until
continuous motor activity disappeared. Following status
epilepticus animals were housed separately. When
seizures stopped, diazepam (2.5 mg/kg, i.p.) was
continued every 30 min. Subcutaneous administration of
warmed sterile saline was given if the animals appeared
lethargic and/or a signiﬁcant drop in weight occurred.
Rats were housed in single cages under standard
conditions in a room with controlled temperature
(22 ± 1 C) and 12/12-h light/dark cycle. The animals
had ad libitum access to food and water. Immediately
following the status epilepticus, rats were manually fed,
if necessary until adequate recovery, and provided with
standard food and also mashed food and apple slices.
Control animals were treated with an equivalent volume
and number of injections of sterile saline.Unilateral intrahippocampal injection of tetanus toxin
Four rats were injected with tetanus toxin and four rats
with saline as controls. Surgical preparation was
performed as previously described (Jiruska et al., 2013),
under ketamine/xylazine anesthesia. A small trephine
opening was drilled over the right hippocampus at
coordinates 4.1 mm caudal to bregma and 3.9 mm
laterally (Paxinos and Watson, 2005). Using a Hamilton
microsyringe and infusion pump (KD Scientiﬁc Inc.,
Holliston, USA) 1 ll of tetanus toxin (Sigma–Aldrich,
Poole, UK) solution was injected into the stratum
radiatum of the right hippocampal CA3 area (depth
3.9 mm). The tetanus toxin solution contained 25 ng of
tetanus toxin in 1 ll of 0.05 M phosphate-buﬀered saline
(PBS; Sigma–Aldrich, UK) and 2% bovine serum
albumin (Sigma–Aldrich, UK). It was injected at 200 nl/
min. The microsyringe was left in the hippocampus for
5 min after the injection ended to avoid the solution
leaking back through the injection track. Control animals
were injected with 1 ll of 0.05 M PBS with 2% bovine
serum albumin. Following surgery, the rats were housed
in single cages and allowed to recover for 2 days.
Subsequently they were monitored for spontaneous
seizures in video monitoring units to verify the
development of spontaneous and recurrent seizures.
Videos were recorded using digital infra-red cameras
(Y-cam Solutions Ltd., Richmond, UK). Animals were
video-monitored for 4 weeks.
All animal procedures were licensed and performed in
strict accordance with the Animal Scientiﬁc Procedures
Act (1986) of the United Kingdom and with Birmingham
University Ethical Review.Sample preparation and immunohistochemistry
Rats were deeply anesthetized with an intraperitoneal
injection of (600 mg/kg) pentobarbitone (Euthatal, Merial
Animal Health, Harlow, UK), perfused transcardially with
saline containing heparin, followed by perfusion with 4%
paraformaldehyde in 0.1 M phosphate buﬀer (PB, pH
7.4). Brains were dissected and the tissue was
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incubation in PB with 15% sucrose, and ﬁnally frozen
before embedding in optical cutting temperature
compound (OCT) and sectioning with a cryostat. Serial
coronal sections of 25 lm of the brain region including
the hippocampus were collected and placed sequentially
on a series of six slides, with 4 sections/slide; the
distance between each section and the next on any
slide was therefore 150 lm. A total of at least eight
such series were collected per animal.
For Cresyl Violet staining, the ﬁrst slide of each series
was consecutively immersed for 5 min in PBS, 50%, and
75% ethanol (EtOH) and then stained in 0.1% Cresyl
Violet (Sigma) for 15 min; after washing in H2O, the
slides were brieﬂy immersed in 75% EtOH, 0.3% acetic
acid, dehydrated, cleared in Histoclear for 5 min and
mounted in DPX, neutral mounting medium (Sigma–
Aldrich).
For immunoﬂuorescence labeling to detect a2d-1,
sections underwent heat-induced antigen retrieval
(10 mM citrate buﬀer, pH 6.0, 0.05% Tween 20, 98 C
for 10 min) prior to blocking with 10% goat serum in the
presence of 0.1% Triton X-100 in PBS for 1 h. Sections
were then incubated with the mouse monoclonal anti-
a2-1 antibody (Sigma, 1:100) in 50% blocking buﬀer forTable 1. Kainic acid study: summary of animals used and histological analysi
ID Treatment Status
Epilepticus
Hippocampal
damage (Cresyl
Violet)
Microglia
activation
(OX42)
Hip
neu
(Ne
1 Kainic
acid
Yes CA1 (bi) + CA3
(bi)
ND ND
2 Kainic
acid
Yes CA1 (bi) + CA3
(bi)
Yes Yes
3 Kainic
acid
Yes CA3 (bi) ND ND
4 Kainic
acid
No CA1 (bi) + CA3
(bi)
Yes Yes
5 Kainic
acid
Yes CA1 + CA3 (bi) ND ND
9* Kainic
acid
Yes CA1 + CA3 (bi) Yes Yes
10 Kainic
acid
Yes CA3 (bi) ND ND
11 Kainic
acid
Yes CA1 + CA3 (bi) Yes Yes
12 Kainic
acid
No No No No
13 Kainic
acid
Yes CA1 (bi) + CA3
(bi)
Yes Yes
6 Saline No No ND ND
7 Saline No No No No
8 Saline No No ND ND
14** Saline No No ND ND
15 Saline No No No No
16 Saline No No No No
Summary of all rats used in the kainic acid study, their treatment and histological analysis. C
least 8 slides per animal) for all brains. The presence of neuronal cell death was detected in
appeared bilaterally (bi). In the kainic acid-treated rats, sections adjacent to those Cresyl V
OX42 and NeuN, in a subset of rats. ND = not determined. +: staining present; ++: st
* Sample with rostral side of right hippocampus deformed.
** Sample not well-perfused.2 or 3 days at 4 C. These sections were also stained
for microtubule-associated protein-2 (chicken Ab against
MAP2, EnCor Biotechnology, Gainesville, FL, 1:1000).
After extensive washing with PBS containing 0.1%
Triton X-100, sections were incubated with biotinylated
goat anti-mouse IgG (1:500) overnight at 4 C and
Streptavidin–Alexa Fluor 488 (1:500) and goat anti-
chicken ab coupled to Alexa Fluor 647 (1:500) overnight
at 4 C. Samples processed for NeuN immunoreactivity
(mouse monoclonal NeuN Ab, Millipore, 1:500) and
OX42 immunoreactivity (mouse monoclonal OX42 Ab,
Abcam, 1:200) were treated in the same way except
that they did not require antigen retrieval. Samples were
then washed and all were stained with 40,6-Diamidino-2-
Phenylindole (DAPI), before mounting in VectaShield
(Vector Laboratories, Burlingame, CA, USA).
In the kainic acid study, experiments were performed
on a total of 16 rats (10 kainate-treated and six saline-
treated, Table 1), of which all were analyzed for
histological abnormalities in the hippocampus by
staining the ﬁrst slide of each series with Cresyl Violet.
This staining was therefore performed on at least 8
slides per animal. Slides from 10 kainate-treated rats
and four saline-treated were stained for a2d-1 and
MAP2 immunoreactivity, selecting one slide from eachs
pocampal
ronal cell loss
uN)
Disruption of a2d-1 staining in
areas of neuronal cell loss
Ectopic a2d-1
staining in CA3
No No
Yes (CA1) No
No No
No ++
No No
Yes (CA1) ++
No No
Yes (CA1) No
No No
Yes (CA1) +
No No
No No
ND ND
ND ND
No ++
No No
resyl Violet staining was performed in the ﬁrst slide of each series (equivalent to at
the pyramidal cell layers of CA1 and/or CA3, as stated. In most cases the damage
iolet stained sections showing hippocampal damage were also stained for a2d-1,
rong staining.
Table 2. Tetanus toxin study: summary of animals used and histological analysis
ID Treatment Status
epilepticus
Spontaneous
seizures
Hippocampal
damage near
injection site
(DAPI)
Microglia
activation near
injection site
(OX42)
Microglia activation
contralateral to
injection site (OX42)
Disruption of a2d-1
staining in areas of
neuronal damage
TTX4 Tetanus
toxin
No Yes (early
onset)
DG+ CA1 CA1 No No
TTX5 Tetanus
toxin
No Yes
(infrequent)
CA1 CA1 No CA1
TTX7 Tetanus
toxin
No Yes (late
onset)
CA1 CA1 + CA1
TTX8 Tetanus
toxin
No No DG CA1 + DG No No
Sal1 Saline No No CA1 + DG CA1 No No
Sal2 Saline No No CA1 CA1 + DG No CA1
Sal3 Saline No No CA1 + DG CA1+ DG No No
Sal4 Saline No No CA1 No No No
Summary of rats used in the tetanus toxin study, their treatment and histological analysis.
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disruption from the Cresyl Violet staining. Adjacent
slides were then processed for NeuN and OX42 staining
(one slide each from one representative series per
animal; from six kainate-treated and three saline-treated
rats). In the tetanus toxin study, four tetanus toxin-
injected and four saline-injected rats were processed
similarly (Table 2).
Image acquisition and analysis and composite
assembly
Cresyl Violet staining was visualized on a Leica MZ7.5
stereomicroscope with a DC300 camera under
transmitted light using the Leica IM50 software (Leica,
Milton Keynes, UK). To produce the hippocampus
composites immunoﬂuorescence images were acquired
with Volocity using an inverted ﬂuorescence microscope
Axiovert 500 M with a 5 objective, converted to JPEGs
and mounted using Autostich software
(www.autostich.net), or manually if the level of signal
was too low for the software. For higher resolution,
confocal images were acquired in a Zeiss LSM 500 M
with a 10 objective (15 lm optical sections) using
Zeiss LSM Image acquisition software.
Spinal nerve ligation (SNL) experiments
These data were obtained during the course of a previous
study (Bauer et al., 2009), but the images in Fig. 6 were
not included in that study. All the experimental detail is
identical to that previously described (Bauer et al., 2009).
RESULTS
Gross morphology and cell loss in the hippocampus
following kainic acid treatment
Rats were repeatedly injected with kainic acid (2.5 mg/kg,
i.p., n= 10), until status epilepticus was observed, which
occurred in 8/10 kainic acid-treated rats (Table 1). For the
control rats, saline was administered (n= 6; Table 1).
Rats were then perfused and the brains removed after
5 weeks.The gross morphology of all the hippocampi was
examined with Cresyl Violet staining, in order to
determine whether neuronal cell death had occurred.
Immunostaining was then performed for a2d-1 and the
dendritic marker MAP2 in all 10 kainic acid-treated and
four of the saline-treated rats. In six kainate-treated and
three saline-treated rats, immunostaining was also
performed for the microglial marker OX-42 (Shaw et al.,
1990) and the neuronal nuclear marker NeuN.
We were interested in whether kainate-induced
seizures and neuronal damage were associated with an
altered expression of a2d-1. From an examination of
gross morphology using Cresyl Violet staining, we found
regions of neuronal cell loss in CA1, CA3 and the hilus
of the dentate gyrus in 8/8 kainate-treated animals
which had developed status epilepticus (Fig. 1A, arrows;
Table 1), and 1/2 kainate-treated rats which did not
develop status epilepticus (Table 1), but not in any
saline-treated rats (Fig. 1B and Table 1). This neuronal
cell loss was conﬁrmed by comparing NeuN
immunostaining, which stains neuronal nuclei (Fig. 1C,
D), with DAPI staining (Fig. 1E, F), which stains all nuclei.Expression of OX42 in hippocampus following kainic
acid treatment
We found that expression of OX42, a marker of microglial
activation (Robinson et al., 1986), was present in the
hippocampus of 4/4 kainate-treated rats examined that
had experienced status epilepticus (Fig. 1G) and in 1/2
rats that did not develop status epilepticus. Expression
of OX42 was seen in both CA1 and CA3 regions
(Fig. 1G), as well as elsewhere in the brain (data not
shown). The location of neuronal damage, determined
by loss of NeuN staining was generally associated with
the appearance of OX42 staining (compare Fig. 1C, G).
In contrast, no OX42 staining was observed in 3/3
hippocampi examined of saline-treated controls or 1/2
kainate-treated rat that did not develop status
epilepticus and did not show any brain damage (Table 1
and Fig. 1H).
Fig. 1. Comparison between hippocampi from kainic acid-treated and control rats. (A, B) Cresyl Violet (cv) staining of a representative hippocampal
section from a kainate-treated rat (A, rat #2) and a saline control rat (B, rat #16). Arrows indicate cell loss in A. (C, D) Composite image of NeuN
immunostaining of a representative hippocampal section from a kainate-treated rat (C, rat #2) and a saline control rat (D, rat #16). (E, F) Composite
image of DAPI staining of a representative hippocampal section from a kainate-treated rat (E, rat #2) and a saline control rat (F, rat #16). (G, H)
Composite image of OX42 staining in adjacent hippocampal sections from kainate-treated rat (G, rat #2) or saline control rat (H, #16). Scale
bar = 1 mm for all panels.
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The a2d-1 subunit has been identiﬁed previously as a
synaptic protein, present particularly in presynaptic
terminals (Taylor and Garrido, 2008; Bauer et al., 2009).
However, a2d-1 is also associated with calcium
channels, including L-type calcium channels, present on
dendrites (Schlick et al., 2010). We found a2d-1 to be
expressed throughout the hippocampus (Fig. 2)
although largely absent from the main cell body layers,
including the granule cells of the dentate gyrus, and the
CA3 and CA1 pyramidal cell layers. The a2d-1 protein is
particularly strongly expressed in the molecular layer
and hilus of the dentate gyrus and in the CA3 stratum
lucidum, but also in the stratum oriens and stratum
radiatum of the CA1 region (Fig. 2A). This distribution is
similar to that found previously using paraﬃn-embedded
rat brain sections and Horseradish Peroxidase staining
(Taylor and Garrido, 2008).
Since a2d-1 is elevated following peripheral nerve
damage in both sensory neurons (Luo et al., 2001;
Newton et al., 2001; Bauer et al., 2009) and in motor
neurons (Bauer et al., 2009; see also Fig. 6), we
examined whether a2d-1 expression was altered in the
hippocampus of kainate-treated rats. We did not
observe any consistent increase of a2d-1 staining in any
region of the hippocampus of any of the kainate-treated
rats; on the contrary there was localized loss of a2d-1immunostaining in the CA1 region, occurring in patches
(Fig. 2B, left panels, arrows), at sites correlating with
CA1 pyramidal neuronal cell loss, shown by NeuN
staining (Fig. 2B, upper right panel, arrow). These
patches are also associated with regions of reactive
gliosis, indicated by OX42 staining (Fig. 2B, lower right
panel, arrow).
At higher power magniﬁcation (Fig. 3), the patches
associated with loss of a2d-1 immunoreactivity are also
associated with a reduction in MAP-2 staining, indicative
of a loss of pyramidal cell dendrites, and an increase in
DAPI staining, likely to be associated with reactive
gliosis (starred areas in Fig. 3A). In Fig. 3B, a region
from the same hippocampus, 1.2 mm rostral to the
damaged area, is shown as a control.
Despite extensive pyramidal neuron loss from the
CA3 region, in the tissue from 9/10 kainic acid-treated
rats (Figs. 1A, C, E, 2B, 3A and 4A), we found that the
strong a2d-1 immunostaining in the CA3 stratum
lucidum was undiminished in these hippocampi (Fig. 4).
In Fig. 4Ai and ii, the CA3 regions from two kainate-
treated rats are shown in comparison with the same
region from a saline-treated rat (Fig. 4B). The CA3
stratum lucidum showing intense a2d-1 staining
corresponds to the layer containing mossy ﬁber terminal
synapses. In some sections, expression of a2d-1 was
also observed to be associated with the stratum oriens
of the CA3 region in kainate-treated rats (Fig. 4Ai). This
was observed in 3/10 kainate-treated rats (Table 1), but
Fig. 2. a2d-1 immunostaining in kainic acid-treated rat hippocampus compared to control hippocampus. (A) Low power composite image of a2d-1
immunostaining (upper panel) in saline control (rat #6), compared with DAPI staining (lower panel). Scale bars = 1 mm. (B) Low power composite
image of staining in hippocampus of a kainate-treated rat (#11) for a2d-1 (left, upper and lower panels are 150 lm apart), NeuN (right upper panel)
and OX42 (right lower panel), showing patchy loss of a2d-1 immunoreactivity, associated with regions of loss of CA1 pyramidal neurons, and up-
regulation of OX42 immunoreactivity (arrows). The sections stained for NeuN and OX42 are consecutive to the upper left section stained for a2d-1.
Scale bars = 1 mm.
M. Nieto-Rostro et al. / Neuroscience 283 (2014) 124–137 129we also observed strong a2d-1 staining in the stratum
oriens of one of the saline-treated rats (Table 1).Eﬀect of intrahippocampal tetanus toxin on OX42 and
a2d-1 staining
For comparison with the kainic acid model, we examined
four rats given an intra-hippocampal injection of tetanus
toxin, with four rats given saline injection as controls.
Three of the tetanus toxin-treated animals developed
spontaneous seizures (Table 1). None of the saline-
treated rats developed seizures.
Hippocampal sections from all rats were subjected to
immunohistochemical analysis of a2d-1 and OX42
immunoreactivity, and counterstained with DAPI. The
pattern of expression of a2d-1 did not show any
signiﬁcant change in any of the samples, except alocalized reduction of immunoreactivity in CA1,
coinciding with the injection track in two of the tetanus
toxin-treated rats (Fig. 5A, top and middle panels,
arrowed), and one saline-treated rat (data not shown).
OX42 signal also appeared along the injection track in
all the tetanus toxin-treated (Fig. 5A, bottom panel,
arrow) and 3/4 saline-treated rats (Fig. 5B left panel). A
minor contralateral expression of OX42 in CA1 stratum
pyramidale was observed in one of the four tetanus
toxin-treated rats that developed late seizures (Fig. 5A,
bottom panel, arrowheads). DAPI staining revealed that
in all cases, there was some cell loss in the CA1
stratum pyramidale and/or lateral dentate gyrus,
associated with the injection track (Fig. 5A middle panel
and 5B right panel), and this neuronal cell death
coincided with the areas showing OX42
immunoreactivity and reduced a2d-1.
Fig. 3. Localized reduction of a2d-1 in stratum radiatum CA1 in ﬁeld associated with loss of pyramidal neurons in kainic acid-treated rats. (A, B)
High power images of a2d-1 (left panel), MAP2 (middle panel), DAPI (right panel) in sections of CA1 and dentate gyrus (DG) associated with
neuronal loss. (A) Shows reduced a2d-1 immunoreactivity in localized areas (asterisks) where dentritic branches are absent, shown by loss of MAP2
immunoreactivity, and DAPI staining shows glial proliferation around the site of pyramidal neuron death. (B) Shows a section 1.2 mm rostral to the
damaged area, as a control. Abbreviations: St.Ori = stratum oriens, St.pyr = stratum pyramidale, St.rad = stratum radiatum, ﬁs = hippocampal
ﬁssure, St.ml = molecular layer, St.gl = granule cell layer. Scale bars = 100 lm.
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injury
In contrast to the results described above, following
physical insult to peripheral axons of somatosensory
nerves, such as SNL (Fig. 6A) and partial sciatic nerve
ligation (PSNL), a2d-1 mRNA and protein is rapidly and
strongly up-regulated on the injured side in dorsal root
ganglion (DRG) neuron somata (Fig. 6B compared to
6C), axons (Fig. 6D compared to 6E) and terminals
(Fig. 6F), as previously described (Newton et al., 2001;
Li et al., 2004; Bauer et al., 2009; Patel et al., 2013).
This ﬁnding represents an aspect of the well-studied
and poorly understood diﬀerence between injury-
induced regeneration in peripheral and central neurons
(Tedeschi, 2011; Cho et al., 2013). Importantly, we
found that a2d-1 was also up-regulated in motor
neurons following SNL, likely to be a consequence of
their axonal damage caused by the ligation (Bauer
et al., 2009) (Fig. 6F, G, H).DISCUSSION
Altered expression of hippocampal a2d-1 following
kainic acid-induced status epilepticus
Many molecular changes have been described in chronic
epileptic tissue. Furthermore, several types of
channelopathies were identiﬁed in neurons from chronic
models of acquired epilepsy. They involve alterations ofkinetics of voltage-gated channels, changes in subunit
composition, expression of new types of channels or
abnormalities of subcellular distribution of speciﬁc
channels (Poolos and Johnston, 2012).
Channelopathies aﬀecting sodium, potassium (Bernard
et al., 2004), calcium (Su et al., 2002) or Ih (Shah et al.,
2004) channels have been described. These alterations
represent molecular, structural and functional changes
which occur during epileptogenesis and are responsible
for increased cellular excitability, altered functional
properties of dendrites and conversion from regular
ﬁring neurons to bursting neurons. Furthermore,
up-regulation of T-type calcium currents was demonstrated
in apical dendrites of CA1 neurons following the
pilocarpine status epilepticus (Su et al., 2002).
The present results indicate that damage to the
central nervous system by kainic acid treatment, which
provokes status epilepticus, followed by delayed
development of spontaneous seizures in rats
(Buckmaster and Dudek, 1997), does not result in a
widespread up-regulation of a2d-1 in the hippocampus,
at least not at 5 weeks post-kainic acid. Although no
overall up-regulation of mossy ﬁber a2d-1 was observed
at the time of this analysis, a reduction of a2d-1 was
observed in regions of CA1 pyramidal cell loss. These
results may indicate that in the regions of kainate-
induced CA1 pyramidal cell loss, the a2d-1 protein
associated with presynaptic CaV channels, in the en
passant synapses from CA3 neurons or Schaﬀer
Fig. 4. a2d-1 staining in the stratum lucidum remains unaﬀected by neuronal cell loss in CA3 stratum pyramidale. (A, B) High power images of a2d-1
(left panel), DAPI (middle panel), and MAP2 (right panel), in two example sections of the CA3 region of hippocampus from two kainate-treated rats
(Ai, #4 and Aii, #13) and a saline-treated rat (B, #6). For clarity the stratum lucidum is delimited by a solid line and the stratum pyramidale by a
dashed line, or dotted line in areas of neuronal cell loss. Abbreviations: St.luc = stratum lucidum, St.pyr = stratum pyramidale, St.ori = stratum
oriens. Scale bar = 100 lm.
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once the target CA1 cells and their dendrites are lost
(see Figs. 2B and 3A). This may therefore represent a
local up-regulation of a2d-1 at neighboring synapses,
although to examine this in the future will require
quantitative analysis at the electron microscopic level.
This increased presynaptic a2d-1 localization could have
increased transmitter release as a consequence (Hoppa
et al., 2012).
Axonal sprouting of mossy ﬁbers has been found to
occur after kainate treatment (McNamara and
Routtenberg, 1995). Possible ectopic expression of a2d-
1 was observed in the stratum oriens of the CA3 region
of some kainate-treated rats that could be associated
with mossy ﬁber sprouting (see Fig. 4Ai), but there was
no up-regulation of a2d-1 protein in cell body regions in
the dentate gyrus, unlike the situation following
peripheral nerve damage.
OX42 up-regulation provides evidence of microglial
activation, and has been shown to be an early response
to brain injury, including kainate-induced lesions
(Akiyama et al., 1994). In the present study we found
widespread bilateral microglial activation following kainicacid administration, in all the rats examined that showed
status epilepticus, and in one of two rats that did not
demonstrate status epilepticus.Comparison of histological changes observed in the
kainic acid and tetanus toxin-induced seizure models
The hippocampi of rats injected with tetanus toxin only
showed localized lesions that mainly coincided with the
injection track, and correspondingly localized
development of OX42 staining. However, three out of
four of these rats developed spontaneous seizures.
When compared with the kainate model and other
status epilepticus models, the tetanus toxin model
possesses distinct features. Tetanus toxin is known to
induce chronic epilepsy with spontaneous and recurrent
seizures but without morphological changes, and in
particular without initial status epilepticus (Jiruska et al.,
2013). It was shown previously that hippocampal
sclerosis characterized by major cell loss was present in
only 10% of animals and aﬀected mainly the CA1 region
(Jeﬀerys, 1992; Vreugdenhil et al., 2002; Jiruska et al.,
2010, 2013). Selective loss of somatostatin-positive
Fig. 5. Histological examination of tetanus toxin-injected rat hippocampus, compared to saline-injected control. (A) Low power composite images in
the hippocampus of a tetanus toxin-treated rat (TTX7), of a2d-1 immunostaining (top panel) showing a localized area of reduced a2d-1 staining
(arrow), DAPI staining (middle panel, same section as top panel) showing pyramidal cell layer disruption due to injection track (arrow), and OX42
staining (bottom panel) from a section 175 lm away from that shown in upper and middle panels, showing microglial activation around injection site
(arrow) and also a small amount along the stratum pyramidale of CA1 of the non-injected side (arrowheads). Scale bars = 1 mm. (B) Low power
composite images of OX42 immunostaining and DAPI staining in the hippocampus (left and right panels, respectively) around the injection track of a
saline-injected rat (Sal3). Scale bars = 0.5 mm.
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tetanus toxin injection (Jeﬀerys et al., 1992). One
consistent structural change is axonal sprouting, both in
the dentate gyrus (mossy ﬁber sprouting shown by
Timm staining) and in the CA1 region. Based on the
results obtained here, we can speculate that changes in
a2d-1 distribution observed in the kainate model can be
attributed to status epilepticus and/or associated
neuronal cell loss.a2d-1 up-regulation is a marker of peripheral nerve
injury
The a2d-1 subunit is expressed in primary aﬀerent DRG
neurons, and is particularly strongly expressed in small
DRG neurons, which include C-ﬁber nociceptors (Bauer
et al., 2009). Cacna2d1, encoding a2d-1, is one of many
genes whose expression is altered followingexperimental peripheral nerve damage. Indeed, a2d-1
mRNA and protein shows up-regulation following
several diﬀerent types of damage to peripheral axons of
DRG neurons, including ligation, chemotherapy and
diabetes-induced neuropathy (Luo et al., 2001, 2002;
Newton et al., 2001; Davis-Taber and Scott, 2006;
Matsumoto et al., 2006; Xiao et al., 2007; Bauer et al.,
2009). Furthermore we have found an alteration in a2d-
1 splice variant expression in DRGs following peripheral
nerve damage (Lana et al., 2013).
The mechanism(s) involved in alteration of gene
expression following somatosensory nerve damage are
thought to involve propagation of an axonal injury-
induced Ca2+ wave to the DRG soma, resulting in
histone deacetylase 5 export from the nucleus, and
activation of gene transcription, a process which has
been found to occur in damaged peripheral but not
central neurons (Cho et al., 2013).
Fig. 6. a2d-1 up-regulation following SNL in rat DRGs and their projections, and in motor neurons. (A) Diagram of the SNL model used to induce
mechanical hyperalgesia. Ipsilateral ligation (ligature, left) of the spinal nerve at the level of L5 (and L6, not shown) aﬀects DRG neurons and their
aﬀerent projections innervating the dorsal horn of the spinal cord. Black circles indicate the location of DRG cell bodies, small black stars indicate
motor neuron cell bodies. (B–E) Representative a2d-1 immunoﬂuorescence images of L6 DRG section (B and C, ipsi- and contralateral respectively)
and dorsal root section (D and E, ipsi- and contralateral respectively), 14 days after SNL. a2d-1 is upregulated in the ipsilateral DRG neurons of all
sizes and also in their projections (green: a2d-1, blue: DAPI). Scale bars = 20 lm. (F) Montage of a2d-1 immunoperoxidase-stained
microphotographs covering a complete L5 spinal cord section 14 days after SNL. a2d-1 immunoreactivity is increased ipsilaterally, in the dorsal
horn (dh), the fasciculus gracilis (fg), and in the cell bodies of motor neurons of the ventral side compared to the contralateral side. White dashed
boxes indicate areas shown in G and H. Diamond () marks a hole in the tissue introduced to identify the contralateral site. Scale bar = 200 lm. Fi:
Insert shows the absence of staining when the primary antibody was omitted. (G, H) Higher power images of the ventral spinal cord, ipsilateral (G)
and contralateral (H) to SNL, showing increased a2d-1 immunostaining in motor neurons on the ipsilateral side (e.g. white arrows in G), Scale
bars = 50 lm. The data for the ﬁgure were obtained during the course of our previous study (Bauer et al., 2009), but the images were not included
in that study.
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models of epilepsy and neuropathic pain
A major diﬀerence between the peripheral somatosensory
nerve damage that results in a2d-1 up-regulation and
kainate-induced neuronal damage is that in the latter
there is loss of CNS neurons, in some cases
accompanied by sprouting of neighboring neurons,
whereas in the former situation, the DRG somata are
not killed by the peripheral nerve insult, and the
damaged peripheral axons can regenerate. However,
although our results do not demonstrate overt or
widespread up-regulation of a2d-1 in hippocampal
neuronal somata, it is possible that there has been
redistribution of a2d-1 at synaptic terminals in areas
aﬀected by neuronal cell loss.
Mechanism of action of gabapentinoid drugs in the
alleviation of neuropathic pain
The high aﬃnity binding site for 3H-gabapentin in the brain
was puriﬁed and identiﬁed to be a2d-1 (Gee et al., 1996;
Brown and Gee, 1998), and it was subsequently found
to bind to a2d-2 with similar aﬃnity (Marais et al., 2001;Gong et al., 2001). Autoradiographic studies then
identiﬁed a2d-1 as the major binding site for 3H
pregabalin in the rat cerebral cortex, hippocampus and
other brain regions, although a2d-2 represented the
main binding site in the cerebellum and interpeduncular
nucleus (Bian et al., 2006).
We have recently shown that the up-regulation of a2d-
1 is required for the rapid development of mechanical
hypersensitivity following PSNL, since this is markedly
delayed in a2d-1 knockout mice (Patel et al., 2013). It is
widely assumed that the up-regulation of a2d-1 in
damaged somatosensory neurons is related to the
eﬃcacy of the gabapentinoid drugs in alleviating
neuropathic pain in humans as well as animal models,
since the gabapentinoids are ineﬀective in mice lacking
a2d-1 (Patel et al., 2013), and in knockin mice in which
a2d-1 is mutated so that it does not bind gabapentinoid
drugs (Field et al., 2006). Nevertheless the mechanism
of action of these drugs at the molecular level still
remains unclear, as they are generally found to produce
little acute inhibition of calcium currents or synaptic
transmission (Sutton et al., 2002; Brown and Randall,
2005; Hendrich et al., 2008). However, some studies
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transmission (Uchitel et al., 2010).
We have found that the a2d-subunits enhance plasma
membrane expression of calcium channels; although the
mechanism still remains unclear, it is thought to involve
traﬃcking of the channels from their site of synthesis to
the plasma membrane (Canti et al., 2005; Bauer et al.,
2010). It is likely that in neurons a2d subunits have
multiple eﬀects on calcium channel distribution, both
associated with long-range calcium channel traﬃcking
from their site of synthesis in the soma to their mainly
presynaptic localization in nerve terminals (Bauer et al.,
2009), and also local eﬀects on calcium channel
localization in membrane micro-domains such as the
active zone and in lipid rafts (Davies et al., 2006; Hoppa
et al., 2012), as well as inﬂuencing the recycling of
calcium channels to the plasma membrane (Tran-Van-
Minh and Dolphin, 2010).
Furthermore, we have found that the gabapentinoid
drugs have an inhibitory eﬀect on calcium currents when
applied over longer time periods, in cultured cells and
neurons (Hendrich et al., 2008; Tran-Van-Minh and
Dolphin, 2010), which we infer is by inhibiting the
traﬃcking of the a2d subunits (Hendrich et al., 2008;
Bauer et al., 2010; Tran-Van-Minh and Dolphin, 2010).
We also observed in vivo that there was less up-
regulation of a2d-1 in nerve terminal zones, after the
induction of somatosensory nerve injury when it was
combined with chronic pregabalin treatment (Bauer
et al., 2009), which might be an eﬀect on long range
axonal traﬃcking, or on lifetime of the protein and its
local recycling at presynaptic terminals. Our evidence
currently indicates that this interference by
gabapentinoids with the function of a2d-1 and a2d-2
results in a reduction of expression of the entire calcium
channel complex at the plasma membrane (Tran-Van-
Minh and Dolphin, 2010; Cassidy and Dolphin, 2014). In
agreement with this, we have also observed inhibitory
eﬀects of chronically applied gabapentinoids on
excitatory synaptic transmission from DRG neuron
terminals (Hendrich et al., 2012).Role of a2d subunits and mechanism of action of
gabapentinoids in epilepsy
The gabapentinoid drugs have therapeutic eﬃcacy as
antiepileptic drugs, although they are generally used in
combination therapy (Marson et al., 2000; Glauser
et al., 2006). In animal models of seizures, gabapentin
has been shown to be eﬀective (Cilio et al., 2001).
However, the mechanism of action of the gabapentinoid
drugs in epilepsy is poorly understood. Although both
gabapentin and pregabalin were ﬁrst developed to
enhance GABA-ergic inhibition in the brain (Taylor et al.,
1992, 2007; Silverman, 2008), it is now clear that they
do not act by mechanisms involving inhibition of GABA
breakdown, or activation of GABA-A or GABA-B
receptors (Taylor et al., 2007; Li et al., 2011).
Furthermore GABA itself does not bind to the a2d
subunits that are now known to be the target for
gabapentinoid drugs (Li et al., 2011).Although it has been found that a2d-1 is the target for
the gabapentinoid drugs in the alleviation of experimental
neuropathic pain in rodents, (Field et al., 2006; Patel
et al., 2013), this is not known for the eﬃcacy of the
gabapentinoids in animal models of epilepsy. An in situ
hybridization study showed that a2d-1 expression was
often more associated with excitatory neurons, and a2d-
2 with inhibitory neurons (Cole et al., 2005). The a2d-1
protein is strongly expressed in the hippocampus,
therefore it is possible that a change in expression of
a2d-1 in epileptic foci might inﬂuence the eﬀectiveness
of the gabapentinoid drugs. In contrast a2d-2 is
expressed in a more restricted pattern, for example it is
strongly expressed in cerebellar Purkinje neurons
(Barclay et al., 2001; Brodbeck et al., 2002). The loss of
expression of a2d-2 in cacna2d2 mutant mouse strains
including ‘‘Ducky’’ results in cerebellar ataxia and spike-
wave epilepsy, and is associated with severe Purkinje
cell dysfunction (Barclay et al., 2001; Brodbeck et al.,
2002; Brill et al., 2004; Donato et al., 2006).
Furthermore CACNA2D2 is disrupted in rare recessive
human cases of epileptic encephalopathy (Edvardson
et al., 2013; Pippucci et al., 2013). Therefore
interference with a2d-2 function might be intuitively less
likely to be the therapeutic target of the gabapentinoids
in epilepsy, compared to disruption of a2d-1 function.
However, this would not exclude the possibility that
there is localized alteration of a2d-2 expression, which
could be a therapeutic target in focal (partial) epilepsy.
Thus it is possible that a2d-2 levels or distribution
might be aﬀected in animal models of epilepsy.
Unfortunately there are currently no available a2d-2
antibodies that are eﬀective in immunohistochemistry,
so at present this cannot be easily tested. However, it
would be extremely useful to examine whether
gabapentin is eﬀective in epilepsy models, using
knockin mice in which either a2d-1 (Field et al., 2006) or
a2d-2 is mutated so that it is gabapentin-insensitive
(Lotarski et al., 2011).
Non-calcium channel functions of a2d proteins
Recently, a2d-1 has been found to interact with
thrombospondins (Eroglu et al., 2009), and this
interaction has been shown to be involved in
synaptogenesis, a process which has been described as
being independent of its function as a calcium channel
subunit. Thrombospondins are a ubiquitous family of
extracellular matrix proteins, which are secreted by
many cell types, including microglia (Chamak et al.,
1995; Eroglu et al., 2009). In a number of experimental
and human epilepsies there is reactive gliosis (Seifert
et al., 2010), microglial activation (Avignone et al.,
2008), and axonal sprouting (Tauck and Nadler, 1985;
McNamara and Routtenberg, 1995; Vreugdenhil et al.,
2002; Sutula and Dudek, 2007). It has also been
proposed that gabapentin inhibits the interaction
between a2d-1 and thrombospondins, and therefore
inhibits synaptogenesis (Eroglu et al., 2009). Although
this might be considered a plausible mechanism of
action of gabapentinoid drugs in treatment of epilepsies,
synaptic remodeling that occurs at epileptic foci (Lew
M. Nieto-Rostro et al. / Neuroscience 283 (2014) 124–137 135and Buckmaster, 2011) is likely to have already occurred
before the onset of treatment with these drugs.
Nevertheless, it is possible that the gabapentinoid drugs
may also modify epileptogenesis and decrease the
consequences of status epilepticus by reducing cellular
damage and seizure frequency (Cilio et al., 2001; Li
et al., 2012).
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